Podcasts about infectious diseases

In this episode of Communicable, Emily McDonald and Josh Davis are joined by Roger Lewis (USA) and Ian Marschner (Australia) to compare and contrast Bayesian and frequentist statistical approaches. The panel discusses the fundamental principles of both methods, common misconceptions, and the extent to which they are often more similar than many realise. Together, they explore their use in clinical trial design, analysis, and reporting, including adaptive trials and sequential learning. Additional topics include sample size misconceptions, regulatory versus clinical thresholds, and the challenges of interpreting post hoc reanalyses of negative trials.This episode was edited by Kathryn Hostettler and the executive producer of Communicable is Angela Huttner.  Further reading:Berry SM, et al. Bayesian Adaptive Methods for Clinical Trials (Chapman & Hall/CRC Biostatistics Series). Boca Raton (FL): CRC Press; 2010. FDA Guidance Document: Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products FDA, 2026, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-productsLee TC, et al. Contextualizing the use of corticosteroids in severe Pneumocystis jirovecii pneumonia through a Bayesian lens. CMI Comms 2025, https://www.cmi-comms.org/article/S2950-5909(25)00082-4/fulltextLivingston EH and Lewis RJ. JAMA Guide to Statistics and Methods, https://jamaevidence.mhmedical.com/Book.aspx?bookId=2742Marschner I. Confidence distributions for treatment effects in clinical trials: Posteriors without priors. Stat Med 2024, doi: 10.1002/sim.10000.Whitehead J. The design and analysis of sequential clinical trials. Revised 2nd ed. Chichester: John Wiley & Sons; 1997.

The name "Dr. Jonas Salk" is synonymous with one of the greatest public health achievements of all time: The Polio Vaccine. The arrival of Salk's vaccine in 1955 was a beacon of hope and reinforced the role science can play to serve the public good. When asked who owned the patent for the vaccine, Salk famously replied, "There is no patent. Could you patent the sun?" In 1994, and just one year before Dr. Salk passed, polio was considered eliminated in North and South America. Today, vaccine hesitancy - driven by a host of reasons - has eroded childhood immunization rates in some parts of the country, and reignited a debate over vaccines as a stress test for public trust in science.rnrnContinuing the work of Dr. Jonas Salk is his son, Dr. Peter L. Salk. A graduate from Harvard University and Johns Hopkins University School of Medicine, he would go on to work in his father's laboratory at the Salk Institute for Biological Studies from 1972 to 1984, and again from 1991 to 1995. Together, they would research the biology and immunotherapy of cancer and autoimmune diseases, and develop an inactivated vaccine for HIV infection. Nowadays, Dr. Salk spends his time educating the public regarding his father's life and work and exploring approaches to reducing the severity of various public health problems. Since 2009, Dr. Salk has served as president of the Jonas Salk Legacy Foundation in La Jolla, California. He is also an adjunct professor at the University of Pittsburgh's School of Public Health, Department of Infectious Diseases and Microbiology.rnrnIn partnership with the Mt. Sinai Health Foundation, join us as Dr. Peter L. Salk sits down in conversation with Dr. Arthur Lavin, retired pediatrician and Co-Founder of Grandparents for Vaccines. Together, they will discuss the Salk legacy, the state of public trust in science, and the future of public health.

In episode 79 of Going anti-Viral, we represent a panel discussion from June 9, 2026, as part of the IAS–USA Dialogue series Emerging Infections and Health Threats. This Dialogue is a must listen as our distinguished panel of infectious disease experts dives deep into some of the most pressing public health challenges facing the world today. Moderated by Carlos del Rio, MD, a Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine, this Dialogue brings together world-class experts Yvonne Maldonado, MD of Stanford University, and Peter Chin-Hong, MD, of the University of California San Francisco. The panel discusses the impact of the World Cup on public health as well as providing updates on current health threats including hantavirus, Ebola, measles, alpha-gal syndrome, and influenza. The panel also provides an update on alpha-gal syndrome and tick-borne diseases, as well as a discussion about an effort by Google to control diseases spread by mosquitoes. Finally, the panelists discuss the risk of the New World screwworm fly to livestock and humans, an outbreak of Campylobacter from the consumption of raw milk, and the impact of the World Cup on influenza in the US.0:00 – Introduction 1:32 – Impact of the World Cup travel on public health7:10 – Lessons learned from the hantavirus outbreak 13:42 – Status of Ebola outbreak, treatment options, and vaccine development25:18 – Update on measles in the US and public health response37:22 – Overview of alpha-gal syndrome and tick-borne diseases42:20 – Update on the Google Debug project45:31 – Risk of the New World screwworm fly to livestock and humans 47:42 – Outbreak of Campylobacter from the consumption of raw milk52:59 – Overview of influenza season in southern hemisphere and risk to the US57:46 – Closing remarks __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Dr. Olga Klinkova, Infectious Diseases clinician at Moffitt Cancer Center and Research Institute, conducts a board review session on Candida Infections targeted towards the medical resident or Infectious Diseases Fellow. Topics discussed include a comparison and contrast of the different Candida species, information on Candida auris, Candidemia, and disseminated (hepatosplenic) candidiasis. Also discussed are novel antifungals used for azole-resistant candidiasis. Guidelines based reference sources are also mentioned.

On episode #108 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 5/21 – 6/3/26. Host: Daniel Griffin and Sarah Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Performance of five mpox antigen-based rapid diagnostic tests tested on lesion swabs from patients with suspected mpox from the Kinshasa province of DR Congo: a diagnostic accuracy study (LANCET: Infectious Diseases) A Phase 3, Randomized Trial ofBulevirtide in Chronic Hepatitis D (NEJM) First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib (CMI: Clinical Microbiology and Infection) Chikungunya Vaccines for Travelers: Unanswered Pragmatic Questions Persist (JID) Bacterial Early Discontinuation of Empiric Antibiotics in Pediatric Haploidentical Hematopoietic Cell Transplant Recipients with Febrile Neutropenia (CID) Methicillin-Resistant Staphylococcus aureus Nasal Swab Utilization as a Predictor for Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections: A Systematic Review and Meta-analysis (OFID) Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial (CID) Fungal The Last of US Season 2 (YouTube) Donor-derived and nosocomial-acquired Candida auris transmission involving solid organ transplant recipients (Infection Control and Hospital Epidemiology) Parasitic Development of a Phase 1 Cryptosporidiosis Controlled Human Challenge Model in Healthy Volunteers Using Current Good Manufacturing Practice Cryptosporidium Parvum Oocysts and Conducted Under an Investigational New Drug Application (JID) Miscellaneous Childhood VaccineHesitancy(NEJM) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Edward Ryan is the director of global infectious diseases at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.T. Ryan, F. Qadri, and J.A. Lynch. Global Cholera-Control Efforts — Progress and Remaining Challenges. N Engl J Med 2026;394:2177-2180.

West Nile was recently discovered in mosquitoes in New Orleans. Let's talk about what the disease is and how it spreads with Dr. Fred Lopez, Professor of Medicine in the Section of Infectious Diseases at LSU Health New Orleans

This member-driven podcast is a benefit of membership of the Arizona Chapter of the American Academy of Pediatrics (AzAAP) and is intended for AzAAP pediatric healthcare members. No information or content in this podcast is intended to substitute or replace a consultation with a healthcare provider or specialist. All non-healthcare providers should reach out to their child's pediatrician for guidance. Music: Wallpaper by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/4604-wallpaperLicense: http://creativecommons.org/licenses/by/4.0/ 

Avec Dre Isabelle Boucoiran, gynécologue-obstétricienne, Marie-Michèle Poirier, infirmière clinicienne à la clinique d'infectiologie mère-enfant (CIME) Caroline Morin, pharmacienne en obstétrique et à la clinique, et Fatima Kakkar, pédiatre infectiologue, nous allons:définir ce qu'est le cytomégalovirus (CMV) et comprendre les risques de complications pour le bébé si l'infection survient durant la grossesse;discuter de l'infection chez la femme enceinte et des mesures non-pharmacologiques pour réduire le risque de transmission fœtale;expliquer le processus de détection, de diagnostic, d'évaluation et de prise en charge des nouveaux-nés atteints d'une infection congénitale à CMV.Références:Boucoiran, I. L'infection à cytomégalovirus (CMV) durant la grossesse. Naître et grandir. Mars 2026. Barton, M., Forrester M., McDonald J. Mise à jour sur l'infection congénitale à cytomégalovirus : la prévention prénatale, le diagnostic néonatal et la prise en charge (2026). Société canadienne de pédiatrie.Boucoiran, I. et autres. « Guidelines No. 420: Cytomegalovirus Infection in Pregnancy », Journal d'obstétrique et gynécologie du Canada, vol. 43, no 7, juillet 2021. jogc.comCMV Canada: https://cmvcanada.com/fr/Guide de CMV Canada pour les femmes en âge de procréer et les futurs parents: https://cmvcanada.com/wp-content/uploads/2025/07/CMV_Awareness_FR_Web.pdf CMV Québec: https://cmvcanada.com/fr/cmv-quebecs/ CHU Sainte-Justine. CMV: complications de grossesse chez la mère. (2018)Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. American Journal of Obstetrics and Gynecology. 2020;223(6):870-883.e81 Leruez-Ville M, Chatzakis C, Lilleri D, et al. Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI). The Lancet Regional Health - Europe. 2024;40:100892. Les invité(e)s et l'animatrice ne déclarent aucun conflit d'intérêt.Idée originale, réalisation et révision, animation et gestion des réseaux sociaux: Émilie Roy-St-PierreCaptation et montage: Philippe Lacroix (depuis janvier 2024), spécialiste en audiovisuel, et Antoine Palardy, (depuis octobre 2025) technicien en audiovisuelConseillère en communication: Pascale Chatagnier (depuis mai 2025) ; Katrine Louis-Seize (janvier 2024 à mai 2025)Technopédagogue: Carl-Philippe Sauvé (depuis janvier 2026)Logo: Équipe des communications et du graphisme du CHU Sainte-JustineMusique: Samuel RossCollègues, ami(e)s et famille, merci pour votre précieux soutien. © 2024-2026, CHU Sainte-Justine. Tous droits réservés.Merci pour l'écoute! Allez mettre une réaction sur vos épisodes préférés, partagez la bonne nouvelle sur Facebook/Instagram et abonnez-vous pour ne rien manquer

In this bonus episode of Communicable, hosts Anne-Grete Märtson and Angela Huttner invite Martin Grobush (University of Amsterdam; ESCMID Emerging Infections Subcommittee) and Daniel Bausch (National University of Singapore, London School of Hygiene & Tropical Medicine, and Geneva Graduate Institute) to discuss the Bundibugyo ebolavirus outbreak currently ongoing in the Democratic Republic of Congo and Uganda. Clinical and virological differences between Bundibugyo and Zaire ebolaviruses are discussed, as are the particular challenges for diagnosis, treatment, and prevention confronting healthcare workers of this outbreak. The episode accompanies two new publications in CMI Communications and CMI:Gupta N, Mora-Rillo M, Gkrania-Klotsas E, et al. Bundibugyo ebolavirus (BDBV): what first responders/clinicians need to know. CMI Communications, 2026; 2 (DOI: 10.1016/j.cmicom.2026.105207) Gupta N, Marta Mora-Rillo, Gkrania-Klotsas E, et al. Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda: rapid assessment from the ESCMID Emerging Infections Subcommittee. Clin Microbiol Infect, 2026 (DOI: 10.1016/j.cmi.2026.05.042)

Paul Sax, MD, FIDSA sits down with comedy-writer, Mike Reiss, and his wife, Denise Reiss, to discuss a lifetime of travel experiences spanning more than 100 countries. From submarine dives and whale sharks to a hospitalization caused by Shigella, they recount remarkable adventures and the health risks that can emerge when exploring the world.

Africa once again has an Ebola outbreak. At this point, it is centered in the so-called Greak Lakes region, with the largest number of cases in the Democratic Republic of the Congo. Uganda has also seen several cases. Sadly this is not new news. But it takes place in the context of a weakened World Health Organization, with the US withdrawal, and a stark memory of the Covid outbreaks. It also is exacerbated by the shuttering of USAID and severe cuts in health funding from the Trump Administration. The United States is insisting that any American that tests positive for the virus would be treated outside of the country, provoking protests in East Africa such as in Kenya. So is the Ebola outbreak a potential pandemic? What has been the most effective means to treat these kinds of outbreaks. And how does it influence the current intense discourses about health care delivery and wellness in the United States. [ dur: 58mins. ] Heather Wipfli is Professor and Clark Leadership Chair in Global Health at the University of Maryland. She is the co-author of Investigating global mental health: Contributions from political science and Network influences on policy implementation: Evidence from a global health treaty. And she has extensive experience in Uganda. Lawrence Gostin is Faculty Director of the O'Neill Institute for National and Global Health Law and is the Founding O'Neill Chair in Global Health Law at Georgetown Law. He is the co-editor of Global Health Security: A Blueprint for the Future and Global Health Law & Policy: Ensuring Justice for a Healthier World (2023). And he is working with the WHO and the Intergovernmental Negotiation Body (INB) to draft a Pandemic Treaty. His opinion posted in Washington Post titled – “Don’t tell Trump, but the U.S. is still a WHO member” and in The Hill where he co-authored  “America's wrong and unlawful response to Ebola must pivot“. Amesha Adalja, Senior Scholar at the Johns Hopkins Center for Health Security, an Adjunct Assistant Professor at the Johns Hopkins Bloomberg School of Public Health. He is the author of Recognition and Management of Infectious Bio-threats and Emerging Pathogens and AI and the Future of Medical Countermeasures to Protect Against Biological Threats. He has served on US government panels tasked with developing guidelines for the treatment of plague, botulism, and anthrax in mass casualty settings, the system of care for infectious disease This program is produced by Ankine Aghassian, Doug Becker and Sudd Dongre. Health, Infectious Diseases, Public Health and Safety, Uganda, Democratic Republic of the Congo

Thabo Shole-Mashao speaks to Prof Linda-Gail Bekker, Director at the Desmond Tutu Health Foundation, about the rollout of the long-acting HIV prevention injection lenacapavir, its potential to reduce new infections, and what it means for South Africa’s fight against HIV. Early Breakfast with Africa Melane is 702’s and CapeTalk’s early morning talk show. Experienced broadcaster Africa Melane brings you the early morning news, sports, business, and interviews politicians and analysts to help make sense of the world. He also enjoys chatting to guests in the lifestyle sphere and the Arts. All the interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from Early Breakfast with Africa Melane For more about the show click https://buff.ly/XHry7eQ and find all the catch-up podcasts here https://buff.ly/XJ10LBU Listen live on weekdays between 04:00 and 06:00 (SA Time) to the Early Breakfast with Africa Melane broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3N Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Can artificial intelligence transform the way healthcare systems detect surgical site infections? Join us for a special episode of AJIC: Science Into Practice featuring our first international guest, Dr. Salma Abbas from the Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore, Pakistan, as we explore innovative research comparing five large language models with traditional SSI surveillance methods. Learn how AI-driven tools demonstrated high diagnostic accuracy and showed promise in supporting infection prevention efforts by reducing the burden of manual chart review while improving the efficiency and scalability of surveillance. From the future of AI in infection prevention to the importance of global innovation in healthcare epidemiology, tune in for a conversation on how this work from Pakistan could help shape the next generation of SSI surveillance worldwide. With special guest: Salma Abbas, MD, MPH, Infectious Diseases and Internal Medicine Physician, Shaukat Khanum Memorial Cancer Hospital & Research Centre

In this episode, we host Professor Meru Sheel to examine whether global health systems are prepared for the next major infectious-disease outbreak. Drawing on her work in infectious-disease epidemiology, vaccine research, emergency preparedness and global health security, Professor Sheel explores the difficult questions now facing governments, public-health agencies and international institutions: how quickly outbreaks can be detected, how effectively information is shared, and how public-health systems can respond before local emergencies become wider international crises. Set against the recent Ebola outbreak in the Democratic Republic of the Congo and Uganda, and the international response to the MV Hondius hantavirus outbreak, this conversation looks at the race between disease spread, surveillance, public trust and political coordination.We discuss why outbreaks test far more than medicine alone. Professor Sheel explains how public-health responses depend not only on vaccines, diagnostics and contact tracing, but also on logistics, risk communication, community engagement and trust in institutions. We explore the difference between individual severity and population-level risk, why a virus can be highly fatal without necessarily posing a pandemic-style threat, and why public-health messaging must warn people without creating panic. The episode also examines the role of the International Health Regulations, the World Health Organization, national governments and multidisciplinary response teams in managing complex, cross-border outbreaks involving cruise ships, repatriation, quarantine, clinical care and international contact tracing.Professor Meru Sheel is Professor of Infectious Diseases and Global Health at the University of Sydney. Her work focuses on epidemiology, vaccine research, outbreak preparedness, emergency response and immunisation systems, particularly across Australia and the Asia-Pacific region. She has worked extensively on the relationship between routine vaccination systems and health emergency preparedness, and her research examines how surveillance, community engagement, vaccine delivery, public-health coordination and equity shape the ability of countries to prevent, detect and respond to infectious-disease threats. The International Risk Podcast brings you conversations with global experts, frontline practitioners, and senior decision-makers who are shaping how we understand and respond to international risk. From geopolitical instability and organised crime to cybersecurity threats and hybrid warfare, each episode explores the forces transforming our world and what smart leaders must do to navigate them. Whether you're a board member, policymaker, or risk professional, The International Risk Podcast delivers actionable insights, sharp analysis, and real-world stories that matter.Dominic Bowen is the host of The International Risk Podcast and Europe's leading expert on international risk and crisis management. As Head of Strategic Advisory and Partner at one of Europe's leading risk management consulting firms, Dominic advises CEOs, boards, and senior executives across the continent on how to prepare for uncertainty and act with intent. He has spent decades working in war zones, advising multinational companies, and supporting Europe's business leaders. Dominic is the go-to business advisor for leaders navigating risk, crisis, and strategy; trusted for his clarity, calmness under pressure, and ability to turn volatility into competitive advantage. Dominic equips today's business leaders with the insight and confidence to lead through disruption and deliver sustained strategic advantage.Subscribe for all our updates!Tell us what you liked!

In episode 78 of Going anti-Viral, Dr Rajesh T. Gandhi joins host Dr Michael Saag to discuss the process of guidelines development. Dr Gandhi is a Professor of Medicine at Harvard Medical School and Principal Investigator and Co-Director of the Harvard University Center for AIDS Research (CFAR). Dr Gandhi is the Vice-Chair of the ACTG, Vice-Chair of the Infectious Diseases Society of America COVID-19 Treatment Guidelines Panel, Chair of the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults, and the Lead Editor for Infectious Diseases, NEJM Clinician. Dr Gandhi and Dr Saag explore the intricate process of developing HIV treatment guidelines, including evidence review, panel selection, and updates on new topics like transgender care and substance use disorders. They discuss how guidelines are created, their impact on clinical practice, and future directions in HIV care.0:00 – Introduction 1:54 – The purpose and impact of guidelines4:00 – Panel composition and selection process6:00 – Guideline structure and key updates12:34 – Emerging topics: transgender care and transplant medicine14:31 – Substance use disorders and treatment innovations16:03 – Evidence-based recommendations and their strength22:07 – Guidelines development process and team dynamics24:42 – Living guidelines versus published documents28:41 – Closing thoughts and future directionsResources: Going-anti-Viral: Episode 32 - Update on the New Antiretroviral Therapy Guidelines - Dr Rajesh GandhiYouTube:  https://youtu.be/G7FQTInz-dY Apple Podcasts:  https://podcasts.apple.com/us/podcast/episode-32-update-on-the-new-antiretroviral-therapy/id1713226144?i=1000678818027 __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

The benefits of getting a shingles vaccine seem relatively straightforward: It will prevent you from getting shingles, a painful rash caused by the same virus that causes chickenpox. But researchers have found a surprising link between getting the shingles vaccine and a lower risk of developing dementia. And that's not the only vaccine that seems to have additional benefits. So what's going on here?  To help explain this research are epidemiologist Pascal Geldsetzer, who studies the association between the shingles vaccine and lower rates of dementia; and physician and epidemiologist Helen Chu, who studies the Flu, RSV and COVID-19 viruses. Guests: Dr. Pascal Geldsetzer is an assistant professor of medicine, epidemiology and population health at Stanford University.  Dr. Helen Chu is a professor of epidemiology, allergy and infectious diseases at the University of Washington.  Other episodes you may enjoy: Study Finds COVID mRNA Vaccines Boost Cancer Treatment As Cervical Cancer Deaths Plummet, Experts Credit HPV Vaccine Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Human Immunodeficiency Virus, or HIV, remains one of the most important infectious diseases in modern healthcare, but advances in antiretroviral therapy have transformed it from a fatal diagnosis into a manageable chronic condition for many patients. In this episode, we'll break down the major medication classes used to treat HIV, discuss how these drugs work, review key adverse effects and drug interactions, and highlight practical nursing considerations that impact patient safety and adherence. Whether you work in acute care, outpatient practice, long-term care, or public health, understanding HIV pharmacology is essential to providing compassionate, evidence-based care for patients living with HIV and AIDS. You can find the full 16+ hour nursing pharmacology review course, including PDF handouts, cheat sheets, practice questions, and on-demand videos at meded101.com!

Viewpoints Explained: How Worried Should You Be About Hantavirus? Cases of hantavirus are on the rise – is this the start of another pandemic? Here's everything you need to know about the rare infection. Host: Ebony McMorris Producer: Amirah Zaveri Linktr.ee | Apple Podcasts | YouTube | SpotifyFacebook: @ViewpointsOnlineX: @viewpointsradioInstagram: @viewpointsradioFull ArchiveContact UsAffiliates & National Syndication Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our editors – Marc Bonten, Erin McCreary, Anne-Grete Märtson, Angela Huttner, and Josh Davis – are back for part two of the ESCMID Global Late Breakers series, summarising five more late-breaking trials presented at ESCMID Global 2026. They discuss the trials' strengths and weaknesses, and whether their results should change practice. The five trials presented in this half of the series are listed below, and links to their respective sessions can be watched and rewatched on the ESCMID Global Virtual Platform. Links to corresponding abstracts and publications where available are provided as well.Conflict of interest/involvement in the trials:Marc Bonten was the chair of the E.mbrace trial's steering committeeJosh Davis is global co-lead of the SNAP trialJosh Davis was a site investigator on the E.mbrace trialAngela Huttner was an independent/unpaid member of the E.mbrace trial's steering committee and an investigator on the precursor phase 1 trial testing the E. coli vaccinePROCALBAN trial (Late-breaking clinical trials in sepsis management)Chowdhury F, et al. Use of Procalcitonin Point-Of-Care Testing to Guide De-Escalation of Antibiotic Therapy in Adult Sepsis Patients in a Tertiary Hospital in Bangladesh: A Randomised Controlled Open-Label Trial, Preprints with The Lancet, doi: 10.2139/ssrn.6541698BENEFICIAL trial (Late-breaking clinical trials in sepsis management) De Cock PA, et al. Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial. Lancet Child Adolesc Health, doi: 10.1016/S2352-4642(25)00385-2  SNAP trial (Late-breaking clinical trials in sepsis management) Bowen A. Adjunctive clindamycin for treatment of Staphylococcus aureus bacteraemia: a randomised controlled trial within the S. aureus Network Adaptive Platform (SNAP), abstractAdjunctive betamethasone treatment of hypoxemic adults hospitalised with Mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial (Late-breaking research from The Lancet)Hagman K, et al. Adjunctive betamethasone treatment of hypoxaemic adults hospitalised with Mycoplasma pneumoniae community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial. Lancet 2026, doi: 10.1016/j.lanepe.2026.101610E.mbrace trial (Vaccines: landmark trials and preventive immunisation)Cohen CA, et al. Randomised phase III trial of a 9-valent vaccine (ExPEC9V) for prevention of invasive Escherichia coli disease (IED) in older adults (E.mbrace), abstractThe Swiss multicentre phase 1, first-in-human trial testing the conjugate E. coli vaccine:Huttner A et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 2017: May;17(5):528-537

Money Anxiety: From Family Lessons To The Money Habits We Lean On Money decisions are rarely just about math. Financial expert Lev Mandel explains how early family lessons, anxiety and repeated habits can shape the way people view money and approach these conversations, and why understanding those patterns can help build a healthier relationship with finances over time. Guest: Lev Mandel, financial expert, author, Money Is Weird. Host: Gary Price Producer: Amirah Zaveri No Shade, No Standard: America's Heat Safety Gap As extreme heat intensifies, outdoor and factory workers are facing risks their jobs were never built to handle. With protections still varying by state, advocates are pushing for updated national standards on shade, water, rest and retaliation-free reporting. Guests:  Pamela Walaski, president, Board of Directors of the American Society of Safety Professionals Katelyn Parady, development and strategic programs liaison, National Council for Occupational Safety and Health Host: Marty Peterson Producer: Amirah Zaveri and Polly Hansen Linktr.ee | Apple Podcasts | YouTube | SpotifyFacebook: @ViewpointsOnlineX: @viewpointsradioInstagram: @viewpointsradioFull ArchiveContact UsAffiliates & National Syndication Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On episode #107 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 5/7 – 5/20/26. Host: Daniel Griffin and Sarah Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) (Gileadl) A Phase 3, Randomized Trial ofBulevirtide in Chronic Hepatitis D(NEJM) Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) (NLM: ClinicalTrials.gov) Andes Hantavirus Outbreak on a Cruise Ship, 2026 (NEJM) Quick takes: Another hantavirus case, polio in 3 countries, NIAID head steps down (CIDRAP) Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial (CID) Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy (CID) Use of Dolutegravir for treatment of HTLV-1 (CID) Use of dolutegravir to treat people living with HTLV-1-associated myelopathy (HAM) (CID) Bacterial Urinary Tract Infection (UTI)-free and Recurrent UTI (rUTI)-Free Survivals Following Bladder Electrofulguration in Women With a History of Antibiotic-Refractory rUTI (OFID) Azithromycin for Preschoolers with Wheezing in the Emergency Department (JAMA) Rapid Respiratory Microbiological Point-of-Care Testing and Antibiotic Use in Primary Care (JAMA Internal Medicine) Fungal The Last of US Season 2 (YouTube) Changes in Epidemiology of Candidemia in the United States With a Focus on Candida auris (CID) Parasitic Impact of introducing RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme (The LANCET) Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement  (JAMA Network OPEN) Febrile Temperature Augents Ring-stage Plasmodium falciparum Adhesion to Brain Endothelial Cells (JID) An Increase in Imported Plasmodium vivax Malaria in New York City: Clinical and Demographic Trends Following Recent Migration (OFID) Miscellaneous The State of Physician Leadership (WittkKieffer) Infectious Diseases Fellowship Curriculum: IDSA Training Program Directors Community of Practice (TPDCOP), Curricular and Educational REsources Workgroup (CREW) (CID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Dr. Isaac Bogoch is a Professor at the University of Toronto in the Department of Medicine, and an Infectious Diseases specialist and General Internist at the Toronto General Hospital with a focus on tropical diseases, HIV, and general infectious diseases. Learn more about your ad choices. Visit megaphone.fm/adchoices

The news that a surf photographer at Raglan had been nibbled by a sea creature, led me to ask you on the show yesterday, what have you been bitten by. Well, it turns out lots of you have been bitten by lots of things we got inundated with your stories, we had tiger bites, sea lions, weta, scorpions, monkeys, the list goes on and on. So today we thought we should talk to an expert about bites, Infectious Disease and Travel Health specialist Dr Marc Shaw chats to Jesse.

Fungal infections are commonly encountered across healthcare settings, ranging from oral thrush and vaginal yeast infections to serious systemic infections in critically ill patients. In this episode, we'll review the major antifungal medications nurses should know, including azoles, echinocandins, polyenes, and topical antifungals. We'll focus on practical nursing considerations such as monitoring for adverse effects, recognizing important drug interactions, administration tips, and patient education points. By the end of the episode, listeners will have a stronger understanding of how antifungal medications work and how nurses play a key role in ensuring safe and effective treatment. You can find the full 16+ hour nursing pharmacology review course, including PDF handouts, cheat sheets, practice questions, and on-demand videos at meded101.com!

Dr. Medaris, Chief of Infectious Diseases at Bay Pines Medical Center in St. Petersburg, Florida, conducts a review of Rickettsial Infections. After starting with an overview of the genus Rickettsia, Dr. Medaris moves on to discuss Rocky Mountain Spotted Fever, R. Parkeri, Mediterranean Spotted Fever, and Rickettsial Pox. African Tick Bite Fever is next discussed, followed by Sylvatic and Murine Typhus. Lastly, Dr. Medaris discusses Coxiella infections. Though not strictly a Rickettsiosis, it shares similarities with the Rickettsial group. The lecture is suitable for board review or for gaining further knowledge regarding these unusual pathogens.

May 22, 2026 ~ Dr. Joel Kammeyer, Associate Professor of Internal Medicine and Chief of Infectious Diseases at Wayne State University, addresses concerns after a plane with a passenger reportedly infected with Ebola was turned away from Detroit. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

What can a rare hantavirus outbreak on a cruise ship tell us about broader public health risks, and are there warning signs closer to home that we may be overlooking? After a Dutch vessel was linked to the Andes strain, questions emerge about how such diseases spread, what makes them dangerous, and whether other threats, including tick-borne illnesses, are already taking hold. We examine what is known about hantavirus, how it compares to more familiar risks, and what it could signal about shifting patterns in human and environmental health. Dr. Fahad Razak, an internist and epidemiologist at St. Michael's Hospital, looks at the implications for surveillance, preparedness, and public awareness. We then turn to a different kind of signal: the ways animals respond to changing conditions. If animals are constantly communicating, what might humans be missing, and could those observations offer insight into environmental change? Amelia Thomas, journalist and author of "What Sheep Think About the Weather," explores how animals interpret their surroundings, what their behaviours might reveal, and whether learning to pay closer attention could deepen our understanding of the forces shaping both animal and human health.See omnystudio.com/listener for privacy information.

Alberta NDP Leader Naheed Nenshi; The Front Bench with Christy Clark, Marco Mendicino, James Moore and Monte Solberg; Infectious Diseases specialist Dr. Isaac Bogoch.

In this powerful and timely episode, Dr Ahmed Seedat — respiratory and general internal medicine consultant, global health specialist, and former policy fellow — joins Dr Krishna Misra, an experienced GP in inclusion health, for an in‑depth exploration of migrant and refugee health. Together with host Dr Rohan Mehra, they unpack the realities facing displaced populations today: from the impact of geopolitical instability and the climate emergency, to the language and stigma shaping public attitudes, to the structural barriers embedded within UK health systems.Through expert insight and frontline experience, the conversation delves into the drivers of forced migration, the consequences of restricted safe routes, the challenges created by the UK asylum backlog, and the complex interplay between trauma, mental health, and chronic disease. Importantly, the episode also highlights a successful collaborative model between primary and secondary care in South East London — demonstrating the power of relationships, community, and advocacy to improve outcomes for some of the most marginalised people in society.Listeners will leave with a richer understanding of migrant health, actionable advice for clinicians, and a hopeful reminder that community truly is a superpower.ResourcesDoctors of the World:Advice line - Doctors of the Worldurgent_care_guidelines.pdf Home 2026 | Refugee WeekBMA:Refugee and asylum seeker health resource updated 2025 BMJ:Knights F, Munir S, Ahmed H, Hargreaves S. Initial health assessments for newly arrived migrants, refugees, and asylum seekers BMJ 2022Initial health assessments for newly arrived migrants, refugees, and asylum seekers | The BMJ Explore our CPD portfolio by your career stageEducation and professional developmentLeadership CPD coursesTeach the teacher – effective teaching skillsEducational supervisorRCP Social MediaInstagramLinkedInFacebookBlueskyMusic Episode 50 onward - Bensound.com  Episodes 1 - 49 'Impressive Deals' - Nicolai Heidlas Any adverts within this podcast may use computer generated voices

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), shares a holistic perspective on health news today. Dr. Jack starts with an announcement the U.S. military will no longer require American troops to get the flu vaccine, based on medical autonomy and religious freedom. The annual flu shot has been required for all U.S. military personnel since the 1950s. The decision has sparked debate with public health organizations, like the National Foundation for Infectious Diseases arguing that high vaccination coverage remains critical for military readiness, particularly in close-quarters living and working environments. Some retired military officials have also criticized the shift, pointing to the historical threat influenza poses to troop readiness.Moving on to the hantavirus, which is responsible for the deaths of three people on a cruise ship, Dr. Jack compares similarities with the start of the COVID-19 pandemic and equates the deaths from Covid were mainly patients already dealing with comorbidities, making them more susceptible than anyone who was healthy. The World Health Organization (WHO) has classified the global risk to the general public from the recent hantavirus outbreak as low. They explicitly state this outbreak is not the next COVID-19, as hantavirus spreads differently and is not highly contagious.Doug and Dr. Jack join forces to address the battle of finding proper supplements, and one they agree is a great made-from-whole-foods option is from Standard Process. Their Diaplex and Zypan vitamins/supplements that trigger better digestive support and response while also helping to balance the sugar control in the system. Standard Process supplements are highly regarded for their "seed-to-supplement" approach, which focuses on whole-food nutrition rather than synthetic isolates. By controlling everything from the soil to the final pill, the brand aims to deliver nutrients in the complex, natural state that the body recognizes and absorbs best.All this and more in this episode of Good Day Health. For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

Transforming healthcare delivery in resource-limited contexts around the world calls for compassionate, innovative solutions. Learn how The Luke Commission is bringing healthcare to the most isolated and underserved in Eswatini through a scalable model for advancing health equity.

Yascha Mounk and Marc Lipsitch also discuss how worried we should be about Hantavirus and Ebola. Marc Lipsitch is the Berberian Professor at Stanford University, with appointments in Infectious Diseases, Biology, and the Center for International Security and Cooperation. In this week's conversation, Yascha Mounk and Marc Lipsitch discuss the good, the bad, and the ugly of gain-of-function research, how scientific incentives may be encouraging risky experimentation—and the recent outbreaks of hantavirus and ebola. If you have not yet signed up for our podcast, please do so now by following this link on your phone. Email: leonora.barclay@persuasion.community Podcast production by Mickey Freeland and Leonora Barclay. Connect with us! Spotify | Apple | Google X: @Yascha_Mounk & @JoinPersuasion YouTube: Yascha Mounk, Persuasion LinkedIn: Persuasion Community Learn more about your ad choices. Visit megaphone.fm/adchoices

On Tuesday's show: The WHO has declared an Ebola outbreak in Africa a global health emergency. We talk with local epidemiologist Dr. Catherine Troisi of UTHealth about how concerned we should be about the disease spreading further, including to Greater Houston.Also this hour: We hear two conversations about artificial intelligence. First, a new study from the University of Houston examines people's attitudes toward AI and data centers. Then, a local law professor explains why he thinks students can beomce better lawyers by using AI tools, something the legal profession may be embracing more broadly than other industries.Then, a Houston businessman was recently acquitted and released by a federal judge in a Foreign Corrupt Practices Act case. Jury convictions in such cases are hardly ever overturned. We find out why it was in this case.And turtles, geckos, and snakes were among the creatures on display recently in Pasadena at Repticon. Brenda Valdivia was there and shares what she learned.Watch

This nursing pharmacology review covers the essential antiviral medications commonly encountered in clinical practice and on nursing exams. The video explains how antiviral drugs work, what infections they treat, and the key nursing considerations for safe medication administration and monitoring. Major medications discussed may include acyclovir, valacyclovir, oseltamivir, antiretroviral therapy, and other commonly prescribed agents. You can find the full 16+ hour nursing pharmacology review course, including PDF handouts, cheat sheets, practice questions, and on-demand videos at meded101.com!

The ESCMID Global Late Breakers series returns to Communicable! Five CMI Communications editors – Marc Bonten, Josh Davis, Angela Huttner, Anne-Grete Märtson, and Erin McCreary – handpicked five late-breaking trials presented at ESCMID Global 2026 to summarise their  findings and discuss whether the results will change their practice. This is part one of the two-part series. Trials presented are listed below and links to their respective sessions can be watched and rewatched on the ESCMID Global Virtual Platform. Links to corresponding publications, if available, and mentioned related articles are provided as well. The FAST trial (Late-breaking research from JAMA)Banerjee R, et al. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia. The FAST Randomized Clinical Trial, doi: 10.1001/jama.2026.5487 Srinivasan A. A Multinational Trial of Rapid Antimicrobial Susceptibility Testing. Is FASTer Better?, doi: 10.1001/jama.2026.5504The CEFMEC trial (Poster session)Hayakawa K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli, Antimicrob Agents Chemother 2023, doi: 10.1128/aac.00510-23The COBRA trial (Late-breaking trials in surgical infection prevention)Overdevest AG, et al. Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. Trials, doi: 10.1186/s13063-026-09524-7The DOTS trial, a secondary analysis (Late-breaking research from JAMA)Lodise, TP, et al. Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial, JAMA 2026, doi: 10.1001/jamanetworkopen.2026.11652 Walls G, et al. Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study, Clin Infect Dis 2026, doi: 10.1093/cid/ciaf522Turner  NA , et al.  Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial. JAMA 2025, doi: 10.1001/jama.2025.12543 Maribavir for clinically significant cytomegalovirus infection in hematopoietic cell transplantation: a real-world retrospective international study of the Infectious Disease Working Party of EBMT (Late-breaking research from The Lancet)Paviglianiti A, et al. Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study. Lancet 2026. doi: 10.1016/S1473-3099(26)00144-1

This episode covers encephalitis.Notes: https://zerotofinals.com/paediatrics/infectiousdisease/encephalitis/Questions: https://members.zerotofinals.com/Books: https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Senate confirms Kevin Warsh as Federal Reserve Chair, 54-45, mostly along party lines except Se. John Fetterman (D-PA) voted yes; House leaders react to President Donald Trump saying he does not "think about Americans' financial situation" when negotiating with Iran over a deal to end the war; Senate defeats for a seventh time an Iran War Powers Act resolution offered by Democrats to force the President to bring the war to a conclusion; President Trump lands in Beijing, China. He meets President Xi Jinping on Thursday; Vice President JD Vance announces new anti-government spending fraud initiatives, including a nationwide six-month moratorium on Medicare hospice or home health providers and warning states to actively investigate Medicaid fraud or risk losing funding; House debates whether to allow year-round sales of E15, a blend of 85% gasoline & 15% ethanol; CIA whistleblower tells the Senate Homeland Security Committee that Dr. Anthony Fauci, former head of the National Institute of Allergy & Infectious Diseases intentionally tried to cover-up the COVID-19 pandemic's origins in a Chinese lab; House marks National Police Week; Former NBA player Jason Collins, first openly gay athlete in the four major American sports, has died. He spoke at the 2016 Democratic National Convention. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode covers meningitis.Notes: https://zerotofinals.com/paediatrics/infectiousdisease/meningitis/Questions: https://members.zerotofinals.com/Books: https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

On episode #106 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 4/23 – 5/6/26. Host: Daniel Griffin and Sarah Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Andes hantavirus outbreak in cruise ship, 11 May 2026(European Centre for Disease Prevention and Control) 2026 Multi-country Hantavirus Cluster Linked to Cruise Ship (CDC: Health Alert Network) "Super-Spreaders" and Person-to-Person Transmission of Andes Virus in Argentina (NEJM) Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update (CID) We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines (CID) Central Nervous System Involvement by Novel Clade 2.3.2.1e H5N1 Avian Influenza Virus in a Paediatric Patient (OFID) Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis (CID) Bacterial Performance of a rapid, visual fingerstick serology self-test for Helicobacter pylori detection and typing: A prospective multicenter diagnostic accuracy study (CMI: Clinical Microbiology and Infection) Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study (LANCET: Infectious Diseases) Beta-Lactam plus Azithromycin or Doxycycline versus Fluoroquinolones in Hospitalized Adult Patients with Community-Acquired Pneumonia: A Systematic Review and Network Meta-Analysis (OFID) Syphilis and the risk of stroke: a nationwide, population-based matched cohort study (CMI: Clinical Microbiology and Infection) Reducing Bacterial Contamination of Blood Bags with a Double Knot (NEJM) Effectiveness and safety of daptomycin versus vancomycin in methicillin-resistant Staphylococci left-side infective endocarditis. Results from a nationwide prospective multicenter cohort. (CMI: Clinical Microbiology and Infection) Fungal The Last of US Season 2 (YouTube) Non-intravenous Amphotericin B: A Review of Localized Administration Routes (Infectious Diseases and Therapy) Parasitic Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial (LANCET: Infectious Diseases) Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies (NEJM) Miscellaneous Interest in Infectious Diseases Among Internal Medicine Resident Physicians: Results From a Nationwide Survey (CID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

What is cultural distress? It is a negative response rooted in a cultural conflict where the patient lacks control over their situation. It results in more physiologic effects on the body resulting in allostatic overload. To prevent this, healthcare practitioners must use strategies such as cultural humility to help patients navigate healthcare. Come find the best ways to deliver culturally sensitive care in any setting.

How prepared are we for high-consequence infectious diseases? In this episode of the 5 Second Rule Podcast, hosts Jess Fargher and Kelly Holmes dive deep into infection prevention strategies and emergency preparedness with Carrie Billman, a seasoned expert. They discuss the critical need for healthcare professionals to understand high-consequence infectious diseases, the role of robust protocols, and the importance of communication and training. Tune in to discover the insights that could save lives in future outbreaks! Hosted by: Kelly Holmes and Jess Fargher About our Guest: Carrie Billman, MHPE, RN, CIC Carrie Billman MHPE, RN, CIC is a senior Infection Preventionist who serves as the Director of Education and Training for the Biocontainment Unit (BCU) at the Johns Hopkins Special Pathogen Center where she leads the design and implementation of training curriculum to prepare clinicians at Johns Hopkins and throughout HHS Region 3 to safely care for patients requiring high-level isolation. She leads the BCU Infection Prevention team and trained observer program and serves as an adjunct faculty for the Johns Hopkins School of Public Health. 

This nursing pharmacology review provides a high-yield overview of the most important antibiotic classes used in clinical practice. The video explains how common antibiotics work, what infections they treat, and the major nursing considerations associated with each class. Key topics include penicillins, cephalosporins, macrolides, fluoroquinolones, tetracyclines, vancomycin, aminoglycosides, and sulfonamides. Emphasis is placed on side effects, black box warnings, allergy considerations, renal dosing, patient counseling, and critical monitoring parameters nurses should recognize in both inpatient and outpatient settings. You can find the full 16+ hour nursing pharmacology review course, including PDF handouts, cheat sheets, practice questions, and on-demand videos at meded101.com!

This episode covers sepsis in children.Notes: https://zerotofinals.com/paediatrics/infectiousdisease/paediatricsepsis/Questions: https://members.zerotofinals.com/Books: https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

The director of the University of Minnesota's Center for Infectious Disease Research said Sunday the hantavirus outbreak on a cruise ship does not pose a serious public threat.The Fargo City Commission will likely approve a new police chief Monday night. Interim Chief Travis Stefonowicz is the sole finalist in the search for Fargo's Chief of Police. Stefonowicz would be replacing Dave Zibolski, who retired last month and drew criticism over the department's use of artificial intelligence to identify and arrest a women for a crime even though she said she'd never been to Fargo. Minnesota is one of several states debating a proposal to allow for "plug-in solar" or "balcony solar." The bill allows people to quickly connect small scale solar systems to their homes or apartments.

As the new chief of Infectious Diseases at Northwestern University Feinberg School of Medicine, Jennie Kwon, DO, is working in a rapidly evolving field rich with opportunities for discovery and impact. Her own research focus is one of the most pressing challenges in medicine today: antimicrobial resistance.  In this episode, she discusses the growing global threat of antimicrobial resistance and why this crisis could fundamentally disrupt modern medicine. 

On Monday's show: We learn why the U.S. Department of Education is investigating HISD and what it could mean for students and their families.And, after two Houston residents were identified as being among those on a cruise ship exposed to the hantavirus, we learn more about the virus and how it's transmitted.Also this hour: We discuss how we evaluate a student's success after graduation -- is salary the best way to measure that?Then, gardening expert Meg Tapp will answer listener questions.And we check in on the Astros' injury-plagued season with Jeff Balke of the Bleav in Astros podcast.Watch

A top official with the National Institute of Allergy and Infectious Diseases has been indicted for allegedly concealing official records on the origins of COVID-19 and for falsifying records.Meanwhile, former FBI Director James Comey has been indicted for allegedly making threats against President Donald Trump.We'll discuss these topics and others in this episode of “Crossroads.”Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

Something's not right in the woods, at least if you're a white-tailed deer. In this episode, the guys dig into chronic wasting disease (CWD), a strange illness reshaping deer populations in many areas of the Lower 48 (and Scandinavia!). It's not caused by a virus or a bacteria, but it is related to mad cow disease. They break down what it is, how it spreads, what's happening inside infected animals, and why it's so dang hard to contain. The deer are not alright… and there's a reason.This episode was recorded on April 23, 2026 at Walton Woods Park in Amherst, NY (a suburb of Buffalo). Episode Notes and Links· Are there different CWD strains in a single animal? Chronic wasting disease isn't a single, uniform pathogen. It's more like a shifting swarm. Infected deer can carry multiple prion “strains” at once, meaning different misfolded shapes of the same protein that behave in slightly different ways. They could spread through the body differently, build up in different tissues, and cause disease at different rates. Lab experiments show this most clearly: when CWD prions are passed through model systems, what looks like one strain can split into multiple distinct variants, or reveal that a mixed population was there all along (e.g., Angers et al. 2010 PNAS; Béringue et al. 2012 Journal of Virology; Li et al. 2010 Journal of Virology). In actual deer, the picture is harder to pin down, but studies comparing prions from different tissues and individuals show real strain diversity and suggest that more than one strain can exist within a single animal (e.g., Angers et al. 2009 Journal of Virology; Moore et al. 2016 Emerging Infectious Diseases). The takeaway is that CWD behaves less like a single disease agent and more like a moving target: a cloud of protein shapes, some dominant, some hidden in the background, that can shift over time, giving the disease more chances to adapt, persist, and potentially jump into new hosts.· Does repeated exposure to CWD reduce incubation time in deer? Repeated exposure to CWD prions does likely shortens incubation time, mainly because prion diseases are strongly dose-dependent. Higher cumulative exposure, whether from a single large dose or many smaller ones over time, can both increase the chance of infection and accelerate disease progression. Experimental studies in deer and elk show that animals exposed to higher or repeated doses tend to develop symptoms faster than those exposed once at low levels. In the wild, this likely plays out through repeated contact with contaminated environments like soil, plants, and carcass sites. That said, factors like genetics and prion strain can still influence how quickly the disease develops in any given animal.· Is CWD the only prion disease that affects wildlife? CWD is the only prion disease currently thriving as a self-sustaining epidemic in wild populations. The others mostly sit at the edges and are livestock diseases that occasionally spill into wildlife or appear in captive/wild interface cases. For example, scrapie occasionally “leaks” into the wild (it has been found in bighorn sheep), but it doesn't take over. It flickers at the edges of livestock systems. Nothing like the landscape-level, self-sustaining spread we see with CWD. That's what makes CWD so concerning: it's not just present in wildlife, it seems to be built for it.· Steve talked about the possibility of vampire bats and wild hogs spreading CWD. What's the story? There's currently no evidence that vampire bats are spreading CWD, but the wild hog story has gotten more interesting recently. Blood-feeding bats like the Common Vampire Bat (Desmodus rotundus) are often mentioned because prions can occur in blood at low levels, but there are no peer-reviewed studies showing bat-mediated transmission, nor any field patterns linking bats to CWD spread. So the bat idea remains speculative. Wild hogs (Sus scrofa), on the other hand, have moved beyond pure theory. A recent peer-reviewed study (e.g., Soto et al. 2025 Emerging Infectious Diseases) detected low levels of CWD prion activity in free-ranging pigs in endemic areas, suggesting they can pick up and carry prions after scavenging infected carcasses. Combine this with earlier work showing prions can survive digestion and still remain infectious (e.g., Nichols et al. 2009 PLoS ONE), it all points to hogs as plausible mechanical vectors: in other words, organisms that can move infectious material without necessarily developing the disease themselves. The takeaway: vampire bats are still a biologically interesting but unsupported idea, while wild hogs are emerging as potential “messy middlemen,” capable of redistributing prions across the landscape, even if they're not a primary engine of CWD transmission, which is still driven by deer-to-deer contact and long-lived environmental contamination.· Why doesn't NYS do more free testing?New York doesn't offer broad, free testing for every deer. Not because it's ignoring CWD, but because it uses a more targeted, strategic approach. There are a few key constraints on broad, free testing:Cost & logistics: Each test isn't just a swab. It involves lab processing (often PCR or amplification assays), trained staff, and sample handling. Scaling that to hundreds of thousands of deer is a major lift.Low prevalence (right now): When disease prevalence is near zero, mass testing tends to return very few positives, so agencies prioritize early detection in hotspots instead.Management strategy: Agencies often invest more in prevention (carcass transport rules, feeding bans, education) than broad surveillance.Hunter participation: “Free for all” testing can overwhelm systems unless tightly managed, and many states have learned that targeted programs get better data per dollar.So NYS is focusing its efforts on where they see it mattering most: high-risk areas, roadkills, sick/dead deer, and zones near known outbreaks—because testing every hunter-harvested deer statewide would be extremely expensive for relatively low yield in a state with no established CWD population.More info on NY's response, as well as what's happening nationally:The NYS Department of Environmental Conservation's page on CWD (including information on how you can help, scroll down to “Members of the Public”)CWD in Captive Deer: DEC's Response in 2024Chronic Wasting Disease Detection and Management: What Has Worked and What Has Not? A report by the CWD Alliance, a nonprofit organization focused on education, coordination, and outreach around chronic wasting disease. It was created to bring together a mix of stakeholders: state wildlife agencies, federal partners, scientists, and hunting/conservation groups to help share reliable information and improve how CWD is managed across North America. Sponsors and Ways to Support UsThank you to Always Wandering Art (Website and Etsy Shop) for providing the artwork for many of our episodes.Support us on Patreon.Works Cited Bian, J., et al. (2022). Transmission of cervid prions to humanized mice demonstrates the zoonotic potential of chronic wasting disease. Acta Neuropathologica Communications, 10, 149.Edmunds, D. R., Kauffman, M. J., Schumaker, B. A., Lindzey, F. G., Cook, W. E., Kreeger, T. J., Grogan, R. G., & Cornish, T. E. (2016). Chronic wasting disease drives population decline of white‑tailed deer. Ecology, 97(3), 620–632.Henderson, D. M., Denkers, N. D., Hoover, C. E., Garbino, N., Mathiason, C. K., & Hoover, E. A. (2015). Longitudinal Detection of Prion Shedding in Saliva and Urine by Chronic Wasting Disease-Infected Deer by Real-Time Quaking-Induced Conversion. Journal of virology, 89(18), 9338–9347. https://doi.org/10.1128/JVI.01118-15Küry, S., et al. (2023). The zoonotic potential of chronic wasting disease—A review. Pathogens, 12(3), 342.Miller, M. W., et al. (2024). U.S. Geological Survey science strategy to address chronic wasting disease. U.S. Geological Survey Circular 1546.Monello, R. J., Powers, J. G., Hobbs, N. T., Spraker, T. R., O'Rourke, K. I., & Wild, M. A. (2014). Endemic chronic wasting disease causes mule deer population decline in Colorado. PLOS ONE, 9(10), e110353.Pirisinu, L., et al. (2024). Zoonotic potential of chronic wasting disease after adaptation in sheep. Emerging Infectious Diseases, 30(12).Sandberg, M. K., et al. (2022). Humanized transgenic mice are resistant to chronic wasting disease prions from reindeer and moose. Journal of Infectious Diseases, 226(5), 933–942.Saunders, S. E., Bartelt‑Hunt, S. L., & Bartz, J. C. (2012). Occurrence, transmission, and zoonotic potential of chronic wasting disease. Emerging Infectious Diseases, 18(3), 369–376.Visit thefieldguidespodcast.com for full episode notes, links, and works cited.

The government is finally catching up to what biohackers have known for decades, and the man helping lead that charge just sat down with Host Dave Asprey to talk longevity science, aging biomarkers, dietary overhaul, AI in medicine, and what a real science-first health agenda actually looks like. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Jim O'Neill served as Deputy Secretary of Health and Human Services and Acting Director of the CDC before being nominated to lead the National Science Foundation in March 2026. Before entering government, he was CEO of SENS Research Foundation, where he led cutting-edge regenerative medicine research targeting mitochondrial mutations, senescent cells, and neocortex rejuvenation. He is a 30-year veteran of health care reform and a genuine longevity insider. Dave and Jim cover the complete rewrite of federal dietary guidelines, the government's new randomized controlled trials on saturated fats, and why grains are no longer the core of a "balanced diet." They dig into a 144 million dollar ARPA H program to establish causal aging biomarkers that will unlock real anti-aging drug development and accelerate the kind of longevity research the SENS Foundation pioneered. Jim explains why current aging clocks and DNA methylation markers are not enough, and what comes next for functional medicine, sleep optimization, and metabolism research. They also break down the CDC's return to its infectious disease core, the future of AI in health care, wearable data for disease surveillance, organ bioprinting, GLP-1s, supplements like vitamin D, peptides, and the right to self-experiment. You will learn: Why the new federal dietary guidelines finally reject grain-centric nutrition and validate what the biohacking world has argued for 25 years How a 144 million dollar government program aims to build the causal biomarkers that will make real anti-aging and longevity drug development possible What Jim thinks about DNA methylation clocks and why better tools are needed to measure aging and human performance How AI is reshaping prescription refills, clinical decision support, Medicare reimbursement, and the future of functional medicine Why Jim wears an Oura Ring and uses sleep optimization data to make daily health decisions The government's evolving stance on peptides, supplements, and therapies that are not patent protected How organ bioprinting using a patient's own cells could solve the organ shortage crisis What real science replication looks like and why the government is now funding it What the CDC is doing to refocus on infectious disease while shedding mission creep How GLP-1s, fitness tracking, and updated nutrition strategies could significantly cut national obesity rates within five years Thank you to our sponsors! - Neuronic | Go to www.neuronic.online Code DAVE for $100 off - iRestore | Reverse hair loss with www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE - Go to timeline.com/dave and save 20% with code DAVE20 - Superstratum Labs | Get Dave's exact home mold detox kit and save 10% at superstratumlabs.com/products/dave Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Jim O'Neill, CDC, HHS, dietary guidelines, saturated fat, aging biomarkers, ARPA H, SENS Research Foundation, longevity, anti-aging, senescent cells, mitochondria, DNA methylation, sleep optimization, Oura Ring, AI healthcare, organ bioprinting, GLP-1, peptides, vitamin D, supplements, functional medicine, biohacking, Dave Asprey, human performance, metabolism Resources: • Learn more at: https://www.hhs.gov/ • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 01:15 – Dietary Guidelines Overhaul 06:48 – Misinformation & Scientific Integrity 10:26 – Longevity vs. Chronic Disease 13:03 – Aging Biomarkers & ARPA-H 14:31 – CDC's Refocus on Infectious Disease 16:55 – Alternative Therapies & Biohacking 19:21 – Health Trackers & Privacy 22:27 – AI in Healthcare 24:01 – Diet, Supplements & School Meals 27:31 – Food Safety, Pesticides & Peptides See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.